MaxCyte to Participate in Upcoming Investor Conferences
01 Juin 2023 - 10:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization, today announced Company management will
participate at the following investor conferences:
- William Blair
43rd Annual Growth Stock Conference Thursday, June 8 at 8:00 a.m.
Central Time
- TD Cowen 2nd
Annual Tools/Dx RevolutionMonday, June 26th at 3:10 PM Pacific
Time
A live and archived webcast of the William Blair
Presentation will be available on the “Events” section of the
MaxCyte investor relations website at
https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR
Adviser Gilmartin
Group David Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media
Relations Spectrum Seismic
Collaborative Valerie Enes +1
408-497-8568 valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure
Gordon Emma Earl / Freddy Crossley Corporate
Broking Rupert Dearden +44 (0)20 7886 2500
UK IR
Adviser Consilium Strategic
Communications Mary-Jane
Elliott Chris Welsh +44 (0)203 709
5700 maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024